Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
5.37
-0.07 (-1.29%)
At close: Oct 3, 2025, 4:00 PM EDT
5.26
-0.11 (-2.05%)
After-hours: Oct 3, 2025, 7:24 PM EDT
Imunon Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
13.54M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 500.00K | - | - |
Dec 31, 2021 | 500.00K | - | - |
Dec 31, 2020 | 500.00K | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IMNN News
- 12 days ago - IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift - GlobeNewsWire
- 15 days ago - IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research - GlobeNewsWire
- 5 weeks ago - IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement - GlobeNewsWire
- 2 months ago - IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call - GlobeNewsWire
- 2 months ago - Imunon, Inc. (IMNN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - GlobeNewsWire
- 2 months ago - IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025 - GlobeNewsWire